Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Form 8-K Table 3 / 10-K / 10-Q MD&A
Latest, FY2021
-6.0%
Period ended Dec 31, 2021
Change on a year earlier
-7.0 pts
1.0% in FY2020
History
5 years
Since FY2017
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | -6.0% | -7.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 1.0% | +3.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -2.0% | -7.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 5.0% | -1.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 6.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%), annual FY2017–FY2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_simponi_ww_exfx_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.